


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Application No.: 09/555,949

Filed: June 6, 2000

T. ISHIKAWA

Phosphonocephem Derivatives, Process for the Preparation of the Same, and Use Thereof

2499 US0P

Atty. Dkt. No.

Art Unit: 1624

Examiner: M. Berch

Allowed: **#13**

Batch:

Paper No.: 9

Supplemental Information Disclosure Statement

Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, applicants request consideration of the references listed on the attached form PTO-1449 under §1.97(d).

Applicants herewith authorize the Commissioner to charge the Applicant's USPTO deposit account number 500799 for the appropriate fee as set forth under 37 CFR §1.17(p) for submission of a Supplemental Information Disclosure Statement.

I hereby state that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call applicants' attorney at (847) 383-3391.

Respectfully submitted,

Elaine M. Ramesh

Elaine M. Ramesh, Ph.D., Reg. No. 43,032

Mark Chao, Ph.D., Reg. No. 37,293

Attorney for Applicants

Customer No. 23115

Dated: January 22, 2002

(847) 383-3391

(847) 383-3372

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
Suite 500, 475 Half Day Road
Lincolnshire, IL 60069 USA

095555949
0000000002 500799
01/22/2002 CC40011
01 FC:126 100.00 CH